Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00513786 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
A Phase 2 study of Endometrial Cancer, sponsored by David O'Malley.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT00513786: Completed Phase 2 study of Endometrial Cancer, sponsored by David O'Malley.
NCT00513786 is a Phase 2 study of Endometrial Cancer that has completed, run by David O'Malley. The registered enrollment target is 38 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00513786, a Phase 2 study of Endometrial Cancer, has completed, sponsored by David O'Malley.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
Purpose of this study is to determine the effectiveness of the drug combination carboplatin, paclitaxel, and bevacizumab(Avastin) in patients with advanced stage endometrial carcinoma.
Primary Outcome
Progressive Disease (PD) is defined at least a 20% increase in the sum of the longest dimension of target lesions, taking as reference the smallest sum of the longest dimension recorded since the treatment start or the appearance of one or more new lesions.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG bevacizumab
Study Locations (1)
Ohio
- The Ohio State University-Division of Gyn Oncology - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2007-08-01 |
| Est. Completion | 2017-01-03 |
| Phase | Phase 2 |
What the finished NCT00513786 record still lists
NCT00513786 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT00513786 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00513786 about?
NCT00513786 is a clinical study titled "Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma". Purpose of this study is to determine the effectiveness of the drug combination carboplatin, paclitaxel, and bevacizumab(Avastin) in patients with advanced stage endometrial carcinoma.
What is the current status of trial NCT00513786?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2007-08-01. Estimated completion is 2017-01-03.
What conditions does trial NCT00513786 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT00513786?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00513786?
This trial is sponsored by David O'Malley, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00513786 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00513786's enrollment target sits among peer trials
38 139th of 181 higher than 43 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI